Global office locator

ICON reports third quarter 2025 results. Quarter three revenue was $2,042.8 million representing an increase of 1.3% on quarter two 2025. Net business wins in the quarter of $2,086 million, representing an increase of 1....

USP compounding may be fast — but is it costing you quality, compliance, and insight? Join our webinar to learn why GMP is the smarter choice for early phase trials. During this session we will discuss: • The differences...

Join ICON at #CPHIFrankfurt, taking place from 28 to 30 October at Messe Frankfurt to discover how our Accelerated Pharmaceutical Solutions are built to meet the demands of a fast-moving industry—combining global reach, ...

ICON is proud to sponsor the World Drug Safety Congress, 4–6 November in Boston, MA. As a global leader in pharmacovigilance, ICON partners with biopharma and medical device companies of all sizes to strengthen patient ...

Are you going to CPHI? If so come along to our VIP in-person event on Tuesday 28th October where our panel of industry experts will discuss the challenges around accelerating timelines and reducing costs in early clinica...

By integrating drug substance, formulation development, real-time manufacturing, and clinical testing, we streamline the entire process—cutting up to 12+ months in development time and significantly reducing costs. Del...

As we begin Day Two of #OCTNordics, we’d like to take a moment to thank everyone who visited the ICON booth yesterday. It’s been a pleasure connecting with industry peers and discussing how ICON is driving innovation acr...

ICON is hosting a webinar on 28 October at 2:00 PM KST to introduce its Strategic Solutions Functional Service Provider (FSP) services and how this model is designed to support sponsors in Korea. The session will provi...

Join ICON at ISPOR Europe 2025 – Booth 824! From health economics and outcomes research (HEOR) to real-world evidence and market access, ICON partners with you to deliver patient-centred solutions that drive value and a...

A survey of obesity developers suggested many multi-indication assets are being developed with trial designs intended for single-indications. Are your development strategies adapted to a multi-indication landscape? Find ...

Sponsors of multi-indication therapies often face the challenge of reconciling regulatory mandates with clinically meaningful outcomes. ICON’s Simon Bruce and Jack Martin discuss trial design considerations for drugs wit...

In this new blog series, we review ISO 14971 (Application of risk management to medical devices) - its history, the principles embedded within it and how it relates to other standards and regulation. For the first editio...